Angiotensin Type 1 Receptor Antagonists Pipeline Insight

DelveInsight’s, “Angiotensin Type 1 Receptor Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angiotensin Type 1 Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Angiotensin Type 1 Receptor Antagonists Understanding

Angiotensin Type 1 Receptor Antagonists: Overview

Angiotensin II receptor blockers (ARBs), formally angiotensin II receptor type 1 (AT1) antagonists, also known as angiotensin receptor blockers, angiotensin II receptor antagonists, or AT1 receptor antagonists, are a group of pharmaceuticals that bind to and inhibit the angiotensin II receptor type 1 (AT1) and thereby block the arteriolar contraction and sodium retention effects of renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They selectively block the activation of the AT1 receptor, preventing the binding of angiotensin II compared to ACE inhibitors.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Angiotensin Type 1 Receptor Antagonists R&D. The therapies under development are focused on novel approaches for Angiotensin Type 1 Receptor Antagonists.

Angiotensin Type 1 Receptor Antagonists Emerging Drugs Chapters

This segment of the Angiotensin Type 1 Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Angiotensin Type 1 Receptor Antagonists Emerging Drugs

 

TRV027: Trevena

Trevena is developing TRV027, a novel AT1 receptor selective agonist designed with Nobel Prize winning technology, as a potential treatment for acute respiratory distress syndrome (ARDS) and abnormal clotting for COVID-19 patients. The potential therapeutic benefit of TRV027 is two-fold: 1) TRV027 competitively binds to the AT1 receptor, which disrupts overactivation caused by the SARS-coronavirus-2 and rebalances hormonal activity within the RAAS. 2) The unique mechanism of action of TRV027 preferentially engages the signaling pathway that promotes downstream reparative effects on lung tissue, as well as reduces abnormal blood clotting associated with COVID-19.

 

Sparsentan: Travere Therapeutics

Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS). Sparsentan is a first-in-class, orally active, single molecule that functions as a high affinity dual-acting antagonist of both endothelin type A (ETA) and angiotensin II subtype 1 (AT1) receptors which are associated with kidney disease progression.

Further product details are provided in the report……..

Angiotensin Type 1 Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Angiotensin Type 1 Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

  • Major  Players working on Angiotensin Type 1 Receptor Antagonists

There are approx. 10+ key companies which are developing the Angiotensin Type 1 Receptor Antagonists. The companies which have their Angiotensin Type 1 Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Travere Therapeutics.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Angiotensin Type 1 Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Angiotensin Type 1 Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Angiotensin Type 1 Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angiotensin Type 1 Receptor Antagonists drugs.

Angiotensin Type 1 Receptor Antagonists Report Insights

  • Angiotensin Type 1 Receptor Antagonists Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Angiotensin Type 1 Receptor Antagonists Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Angiotensin Type 1 Receptor Antagonists drugs?
  • How many Angiotensin Type 1 Receptor Antagonists drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angiotensin Type 1 Receptor Antagonists?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Angiotensin Type 1 Receptor Antagonists therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Angiotensin Type 1 Receptor Antagonists and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Angiotensin Type 1 Receptor Antagonists: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Angiotensin Type 1 Receptor Antagonists – DelveInsight’s Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

Sparsentan: Travere Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

DMX-200: Dimerix Bioscience

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

ATB-101: Autotelic Bio

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

BKC 005: Boryung Pharmaceutical

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Angiotensin Type 1 Receptor Antagonists Key Companies

Angiotensin Type 1 Receptor Antagonists Key Products

Angiotensin Type 1 Receptor Antagonists- Unmet Needs

Angiotensin Type 1 Receptor Antagonists- Market Drivers and Barriers

Angiotensin Type 1 Receptor Antagonists- Future Perspectives and Conclusion

Angiotensin Type 1 Receptor Antagonists Analyst Views

Angiotensin Type 1 Receptor Antagonists Key Companies

Appendix

List of Table

Table 1: Total Products for Angiotensin Type 1 Receptor Antagonists

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Angiotensin Type 1 Receptor Antagonists

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Trevena
• Travere Therapeutics
• Hanmi Pharmaceutical
• ARKAY Therapeutics
• Novartis
• Dimerix Bioscience
• Autotelic Bio
• LG Chem
• Boryung Pharmaceutical

 

Forward to Friend

Need A Quote